Mark Coffin

Mark Coffin has over 29 years of experience in the pharmaceutical industry. Mark began their career at GlaxoSmithKline, where they served as a Director for 25 years. In 2015, they joined Ocera Therapeutics as the Vice President of Pharmaceutical Development and Manufacturing. At Ocera Therapeutics, Mark was responsible for various aspects of the physical product, including API chemistry, formulation development, and regulatory submissions. In December 2017, Ocera Therapeutics merged with Mallinckrodt Pharmaceuticals, and Mark completed the transition of their responsibilities to Mallinckrodt in March 2018. In 2018, they joined Mycovia Pharmaceuticals as the Senior Director of Pharmaceutical Development. Mark Coffin's expertise lies in pharmaceutical development and manufacturing.

Mark Coffin completed their education at Purdue University from 1978 to 1983, studying Pharmacy. Mark then pursued a PhD in Pharmaceutics from The University of Texas at Austin, graduating between 1986 and 1990.